Phenoconversion & Functional PK
Evidence supporting the distinction between inherited genotype and a patient's current functional metabolic state.
SCIENCE & IP
From Science to Better Medication Decisions.
Published science. Patented innovation. Transparent evidence boundaries.
From Genotype to Clinical Action
Genetic variation provides a starting point. Medications and other supported patient factors can change functional drug-processing context.
1GENOTYPE
→Inherited metabolic starting point.
2PHENOCONVERSION
→Medication and supported patient factors may alter enzyme or transporter activity.
View Evidence →3TruTYPE®
→Estimated functional PK state.
View Evidence →4EXPOSURE
→Potential increased, unchanged or decreased medication exposure.
View Evidence →5TruRISK™
→Patient-specific medication-risk context.
View Evidence →6TruSELECT™
Evidence-supported medication and dosing options for clinician evaluation.
Drug Exposure & Quantitative PK
Evidence examining how genetic variation, inhibition, induction and concomitant medications can alter systemic exposure.
Drug–Drug–Gene Interactions
Evidence examining combined genotype and medication effects on functional metabolism and exposure.
Scientific Boundaries
Published evidence supports the underlying pharmacology. Proprietary TruTYPE and TruRISK outputs require independent validation and are not presented as measured real-time enzyme activity or calibrated event probability.